US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
Siblings trying to make US water polo teams for Paris Olympics
WALNUT, Calif. (AP) — Chase Dodd started swimming when he was just a kid. Once he began playing wate2024-05-22Government rejects Auckland Mayor Wayne Brown's demands over rates, GST
Wayne Brown. Photo: Glenda Wakeham2024-05-22Fire at industrial building in Ōtaki
Smoke from the fire seen about 7am Friday. Photo: Supplied / Tamara Savage2024-05-22Person seriously injured, another dead after Browns Bay assault
Photo: 123RF2024-05-22Climber found dead on Denali, North America's tallest peak
ANCHORAGE, Alaska (AP) — A climber was found dead on North America’s tallest peak, Denali, on Monday2024-05-22London police say chemical attacker presumed dead
London police have been searching for Abdul Shokoor Ezedi since the attack on 31 January, 2024. Phot2024-05-22
atest comment